Your browser doesn't support javascript.
loading
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel, Viola; Held, Gerhard; Ziepert, Marita; Witzens-Harig, Mathias; Holte, Harald; Thurner, Lorenz; Borchmann, Peter; Viardot, Andreas; Soekler, Martin; Keller, Ulrich; Schmidt, Christian; Truemper, Lorenz; Mahlberg, Rolf; Marks, Reinhard; Hoeffkes, Heinz-Gert; Metzner, Bernd; Dierlamm, Judith; Frickhofen, Norbert; Haenel, Mathias; Neubauer, Andreas; Kneba, Michael; Merli, Francesco; Tucci, Alessandra; de Nully Brown, Peter; Federico, Massimo; Lengfelder, Eva; di Rocco, Alice; Trappe, Ralf; Rosenwald, Andreas; Berdel, Christian; Maisenhoelder, Martin; Shpilberg, Ofer; Amam, Josif; Christofyllakis, Konstantinos; Hartmann, Frank; Murawski, Niels; Stilgenbauer, Stephan; Nickelsen, Maike; Wulf, Gerald; Glass, Bertram; Schmitz, Norbert; Altmann, Bettina; Loeffler, Markus; Pfreundschuh, Michael.
Afiliação
  • Poeschel V; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany. Electronic address: viola.poeschel@uks.eu.
  • Held G; Department of Internal Medicine 1, Westpfalz-Klinikum, Kaiserslautern, Germany. Electronic address: gheld@westpfalz-klinikum.de.
  • Ziepert M; Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany.
  • Witzens-Harig M; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Thurner L; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.
  • Borchmann P; Department of Hematology and Oncology, University Hospital of Cologne, Cologne, Germany.
  • Viardot A; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
  • Soekler M; Department of Internal Medicine II, University Hospital Tuebingen, Tuebingen, Germany.
  • Keller U; Department of Internal Medicine III, Klinikum Rechts der Isar der TU München, Munich, Germany.
  • Schmidt C; Department of Medicine III, University Hospital, Munich, Germany.
  • Truemper L; Department of Hematology and Oncology, Georg August University of Goettingen, Goettingen, Germany.
  • Mahlberg R; Department of Internal Medicine I, Klinikum Mutterhaus der Borromaerinnen, Trier, Germany.
  • Marks R; Department of Hematology and Oncology, University Medical Center, Freiburg, Germany.
  • Hoeffkes HG; Klinikum Fulda Tumorklinik, Fulda, Germany.
  • Metzner B; Department of Hematology and Oncology, Klinikum Oldenburg, Oldenburg, Germany.
  • Dierlamm J; Department of Internal Medicine II, University Hospital Eppendorf, Hamburg, Germany.
  • Frickhofen N; Department of Internal Medicine III, Dr Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany.
  • Haenel M; Department of Internal Medicine III, Küchwald Hospital Chemnitz, Chemnitz, Germany.
  • Neubauer A; Department of Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany.
  • Kneba M; Department of Internal Medicine II, City Hospital Kiel, Kiel, Germany.
  • Merli F; Hematology Azienda Unità Sanitarie Locali-Istituto di Ricovero e Cura a Carattere Scientifico di Reggio Emilia, Reggio Emilia, Italy.
  • Tucci A; Hematology Azienda Socio Sanitaria Territoriale Spedali Civili Brescia, Brescia, Italy.
  • de Nully Brown P; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Federico M; Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, University of Modena and Reggio Emilia, Modena, Italy.
  • Lengfelder E; Department of Internal Medicine III, University Hospital Mannheim, Mannheim, Germany.
  • di Rocco A; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Trappe R; Department of Internal Medicine II, Evangelisches Diakonie-Krankenhaus, Bremen, Germany.
  • Rosenwald A; Institute of Pathology, University of Wuerzburg, and Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany.
  • Berdel C; Department of Radiooncology, Saarland University Medical School, Homburg/Saar, Germany.
  • Maisenhoelder M; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.
  • Shpilberg O; Department of Hematology, Rabin Medical Center, Beilinson Hospital, Petah-Tiqwa, Israel.
  • Amam J; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.
  • Christofyllakis K; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.
  • Hartmann F; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.
  • Murawski N; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.
  • Stilgenbauer S; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.
  • Nickelsen M; Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany.
  • Wulf G; Department of Hematology and Oncology, Georg August University of Goettingen, Goettingen, Germany.
  • Glass B; Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany.
  • Schmitz N; Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany.
  • Altmann B; Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany.
  • Loeffler M; Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany.
  • Pfreundschuh M; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.
Lancet ; 394(10216): 2271-2281, 2019 12 21.
Article em En | MEDLINE | ID: mdl-31868632
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B / Rituximab / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Região como assunto: Asia / Europa Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B / Rituximab / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Região como assunto: Asia / Europa Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article